Page 3 - Nasdaq Crsp News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nasdaq crsp. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nasdaq Crsp Today - Breaking & Trending Today

CRISPR Therapeutics AG (NASDAQ:CRSP) Shares Sold by B & T Capital Management DBA Alpha Capital Management

B & T Capital Management DBA Alpha Capital Management decreased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 3.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 44,738 shares of the company’s stock after selling 1,411 shares during […] ....

Samarth Kulkarni , Raju Prasad , Wells Fargo Company , Loring Wolcott Coolidge Fiduciary Advisors , Securities Exchange Commission , Exchange Commission , Royal Bank , Headlands Technologies , Tradewinds Capital Management , Therapeutics Company Profile , Bluepath Capital Management , Capital Management , Free Report , Path Capital Management , Loring Wolcott , Coolidge Fiduciary Advisors , Chardan Capital , Get Free Report , Visit Holdingschannel , Crispr Therapeutics , Nasdaq Crsp , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

McGuire Investment Group LLC Sells 809 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

McGuire Investment Group LLC lowered its stake in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 1.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 58,597 shares of the company’s stock after selling 809 shares during the quarter. McGuire […] ....

Samarth Kulkarni , Raju Prasad , Tradewinds Capital Management , Securities Exchange Commission , Pinnacle Holdings , Mcguire Investment Group , Needham Company , Headlands Technologies , Wells Fargo Company , Therapeutics Company Profile , Morgan Stanley , Free Report , Guire Investment Group , Capital Management , Spire Wealth Management , Wealth Management , Exchange Commission , Get Free Report , Truist Financial , Crispr Therapeutics , Nasdaq Crsp , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

IMA Wealth Inc. Sells 255 Shares of CRISPR Therapeutics AG (NASDAQ:CRSP)

IMA Wealth Inc. cut its holdings in CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 1.0% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 25,517 shares of the company’s stock after selling 255 shares during the period. IMA Wealth Inc.’s […] ....

Samarth Kulkarni , Jamesr Kasinger , Capital International Investors , Blackrock Inc , T Rowe Price Investment Management Inc , Securities Exchange Commission , Ima Wealth Inc , Therapeutics Company Profile , Wealth Inc , Pricet Rowe Associates Inc , Free Report , International Investors , Rowe Price Investment Management , State Street Corp , Street Corp , Trading Down , Get Free Report , Chardan Capital , General Counsel James , Visit Holdingschannel , Crispr Therapeutics , Nasdaq Crsp , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

CRISPR Therapeutics AG (NASDAQ:CRSP) Position Trimmed by Federated Hermes Inc.

Federated Hermes Inc. cut its position in shares of CRISPR Therapeutics AG (NASDAQ:CRSP – Free Report) by 0.1% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 508,100 shares of the company’s stock after selling 658 shares during the quarter. Federated Hermes Inc. owned […] ....

Jamesr Kasinger , Samarth Kulkarni , Interchange Capital Partners , Wells Fargo Company , Needham Company , Invesco Ltd , Securities Exchange Commission , Exchange Commission , Hermes Inc , Envestnet Asset Management Inc , Federated Hermes , Free Report , Capital Partners , Asset Management , Nordea Investment Management , Investment Management , Wells Fargo , Chardan Capital , General Counsel James , Get Free Report , Visit Holdingschannel , Crispr Therapeutics , Nasdaq Crsp , Sec Filings , Hedge Fund Holdings , Institutional Investor Holdings ,

CRISPR Therapeutics (NASDAQ:CRSP) Price Target Raised to $90.00 at Needham & Company LLC

CRISPR Therapeutics (NASDAQ:CRSP – Free Report) had its price target raised by Needham & Company LLC from $88.00 to $90.00 in a report issued on Wednesday morning, Benzinga reports. The firm currently has a buy rating on the stock. Other research analysts also recently issued reports about the company. Royal Bank of Canada increased their […] ....

Samarth Kulkarni , Jamesr Kasinger , Therapeutics Company Profile , Morgan Stanley , Royal Bank , Swiss National Bank , Jump Financial , Needham Company , Capital Advisors Inc , Wolfe Research , Free Report , Get Free Report , General Counsel James , National Bank , Crispr Therapeutics , Nasdaq Crsp , Boost Price Target , Needham Company Llc ,